Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body × Cetuximab × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT07252739 2026-04-17

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Phase 2 Recruiting

130 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT04428151 2025-12-04

LEAP-009

Phase 2 Completed

408 enrolled 17 charts

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT03358472 2025-12-03

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Phase 3 Completed

89 enrolled 14 charts

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02358031 2025-07-18

MK-3475-048

Phase 3 Completed

882 enrolled 50 charts 1 FDA

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT06647563 2024-10-18

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

Phase 3 Not yet recruiting

355 enrolled

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT02563002 2024-10-03

KEYNOTE-177

Phase 3 Completed

307 enrolled 16 charts 1 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT02252042 2023-07-17

MK-3475-040

Phase 3 Completed

495 enrolled 32 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Squamous Cell

NCT03342352 2019-12-20

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Phase 3 Withdrawn

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Clinical Trials

MK-3475-C66

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

LEAP-009

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

MK-3475-048

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

KEYNOTE-177

MK-3475-040

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)